Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMD

home / rapid-readouts / impact-of-disease-activity-criteria-on-dosing-interval-assignment-in-clinical-trials-in-namd

Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).

© 2024 MJH Life Sciences

All rights reserved.